Navigation Links
Immucor Announces Record Fiscal Third Quarter Results
Date:4/1/2008

trument sales for 39 Galileo(R) and ECHO(TM) instruments were deferred in this manner while the associated cost of sales of approximately $2.4 million was expensed. As of February 29, 2008, deferred instrument revenues, including deferred service revenues, totaled $24.8 million. Reagent gross margin grew to 81.0% during the third quarter of fiscal 2008 compared to 77.6% in the same period last year.

"We are very pleased with our outstanding quarterly financial results and the number of Echo orders received in the United States, which exceeded our expectations" said Dr. Gioacchino De Chirico, President and Chief Executive Officer. "In the third quarter we received 54 Echo orders in North America and another 16 Echo orders in the rest of the world for a total of 70 in the quarter. We also received orders for 11 Galileo in North America in the third quarter, and another 11 Galileo orders in the rest of the world for a total of 22 in the quarter." Commenting further, Dr. De Chirico stated, "Based on the very positive results of the Galileo Echo launch and continued Galileo placements we believe we can achieve market share gains and revenue growth through an increasing number of instrument placements. Third quarter results were positively impacted as 19 of the 20 Galileo instruments previously sold to the American Red Cross went live in the quarter. As of February 29, 2008, the Company had received orders for a total of 562 Galileo instruments worldwide, including 245 in North America and 317 in the rest of the world, and 516 of these instruments were generating reagent revenues, an increase of 38 in the quarter. As of February 29, 2008, the Company had received orders for a total of 155 Echo instruments worldwide." Dr. De Chirico also noted, "Our recently announced proposed acquisition of BioArray Solutions Ltd. means the Company is positioning itself at the leading edge of technology in blood banking. Our excellent current results, good growth prospects for our
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Immucor Schedules First Quarter Earnings Release and Conference Call
2. Immucor Announces Record Fiscal First Quarter Revenues
3. Immucor, Inc. Appoints New Chief Financial Officer
4. Immucor Announces Update to Second Quarter Conference Call Number
5. Immucor, Inc. Adds Director to Board
6. Immucor Schedules Third Quarter Earnings Release and Conference Call
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Case Studies in the Management of PK/PD Data Will be Presented ... ... France, MOUNTAIN VIEW, Calif., Sept. 25 Pharsight,Corporation (OTC ... optimizing clinical drug development, today,announced that Dan Weiner, Ph.D., Senior Vice ...
... Call it Quits collaborative launches new Minnesota Clinic Fax Referral ... ... 25 Call it Quits,-- a newly named collaboration among Minnesota,s major ... it easier,for physicians and other healthcare providers to help their patients who,want ...
... the Cure(TM) Kicks Off October 1; Join the Breast ... Cancer Movement by Wearing Pink In October, DALLAS, Sept. ... together to increase awareness of breast cancer,a disease that without a ... you can join them. (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ) The ...
... Australian researcher has completed some pioneering work which is ... , Professor Patrick Tams 27-year exploration has mapped ... embryos. It reveals how cells direct themselves to ... He was (today) awarded recognition at a national conference ...
... PGL; Nasdaq: PGLA) announced today that its investigational,anti-cancer ... by the U.S. Food,and Drug Administration (FDA). The ... for the prevention of tumor recurrence following curative ... liver,cancer). Under the FDA Modernization Act of ...
... ARBOR, Mich. -- Despite decades of advances in diabetes ... likely than whites to have their blood sugar under ... nationally representative study finds. That puts them at a ... foot amputation and other long-term diabetes complications. , ...
Cached Medicine News:Health News:Pharsight to Host European Software Conference 2Health News:Health Organizations Join Forces Around Quit-Smoking Help 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 3Health News:Explorer completes the map ... for the body's blueprint 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 2Health News:Older blacks and Latinos still lag whites in controlling diabetes 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 4Health News:Older blacks and Latinos still lag whites in controlling diabetes 5
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. The classic Goldmann Glass....
For the binocular slit observation of the pupil, the macula, its surroundings out to 30 as well as the central vitreous body sections. Easy to use, lightweight glass provides a direct image....
... philosophy of the Quad 4™ Intramedullary Nailing ... that could be used for the widest ... of the system were to minimize the ... inventory, with one system that could address ...
Medicine Products: